Sanofi is set to significantly expand its operations in India by investing $437 million and doubling its workforce. This follows reports of similar expansion plans at its Hyderabad site. The company's consumer arm has reportedly attracted bids from Advent, PAI, and CD&R. In partnership with the NAACP, Sanofi vows to advance health equity. It's also seen success in overturning a key patent by Amgen at the UPC. Amid positive moves, Sanofi faces criticism for cruelty-free product alternatives. The UPC revoking a patent in the cholesterol drug battle between Sanofi, Regeneron, and Amgen is a definite triumph for Sanofi. The multinational is also making strides in the pharmaceutical industry with AI-powered clinical trials and AI-driven drug development. Controversially, Sanofi announced a voluntary recall of Allegra and Combiflam suspensions in India. An investment of up to $1.6 billion in Germany was hinted at, focusing on insulin production. Sanofi maintains a proactive stance towards decarbonization in healthcare, despite liability issues regarding Plavix in Hawaii. Performance indicators are mixed, with good news in Europe but bad news in the US regarding their COPD bid for Dupixent.
Sanofi News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 21 Jul 2024 19:06:00 GMT - Rating 3 - Innovation 7 - Information 6 - Rumor -2
